Abstract

A 1% reduction in HbA1c levels increases the risk of macrovascular and microvascular complications in diabetes. SGLT-2 inhibitors are a group of drugs that inhibit sodium-glucose cotransporter 2 in the renal proximal tubules. They lead to a decrease in glucose reabsorption and glucosuria, lowering blood sugar. The aim of the present analysis was to investigate the level of glycemic control in patients with type 2 diabetes mellitus treated with SGLT-2 inhibitors. Out of a total of 57 patients (100%) treated with SGLT-2 inhibitors, 31 were men - 54.4%, and 26 were women - 45.6%. Analyzing the data from our study, a favorable, statistically significant reduction in blood glucose was reported at each follow-up stage with treatment with SGLT-2 inhibitors. For glycated hemoglobin, it was found that the difference between its mean values ​​at the beginning of 8.52±1.60% and after 6 months was 7.17±1.08%, amounting to 1.69%, was statistically significant.

Key words: type 2 diabetes mellitus, SGLT-2 inhibitors, glycemic control

Download full text as PDF file